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Sanguis draxonis (SD), also known as “Dragon’s Blood”, is a traditional herb medicine that has been used to treat a
variety of complications with unknown mechanisms. Recent studies show that SD displays immunosuppressive
activities and improves symptoms of type I diabetes in animal models. However, the mechanisms underlying SD’s
immunosuppressive actions are not completely understood. The voltage-gated Kv1.3 channel plays a critical role in
the pathogenesis of autoimmune diseases by regulating the functions of both T cells and B cells. Here we investigated
the effect of SD and one of its active components loureirin B (LrB) on Kv1.3. Both SD and LrB inhibited Kv1.3-mediated
currents, produced a membrane depolarization, and reduced Ca2+ influx in Jurkat T cells. In addition, application of LrB
inhibited phytohemagglutinin (PHA)-induced IL-2 release from activated Jurkat T cells. Furthermore, point mutations in
the selective filter region significantly reduced the inhibitory effect of LrB on Kv1.3. The results of these experiments
provide evidence that LrB is a channel blocker of Kv1.3 by interacting with amino acid residues in its selective filter
region. Direct inhibition of Kv1.3 in T cells by SD and LrB might be the cellular and molecular basis of SD-mediated
immunosuppression.
Keywords: Loureirin B, Sanguis draxonis, Kv1.3 channels, IL-2Introduction
Plant-derived natural compounds not only play a critical
role in ancient medicine [1] but also become unique
tools to dissect disease mechanisms as well as important
reservoirs of potential new drugs [2-5]. SD, also called
“dragon’s blood”, is a famous herb medicine used for a
variety of applications including blood stasis, oxidative
stress, inflammation, tumors and immune suppression [6].
The immunomodulatory activity of SD was proposed to
involve inhibition of both classical (CP) and alternative
(AP) pathways of complement system as well as prolifera-
tion of activated T-cells [7], suggesting that SD might be
able to inhibit autoimmune diseases. In fact, recent studies
have shown that SD is effective in reducing glycemia and
increasing insulin sensitivity in diabetic rats [8,9]. Further
studies demonstrated that oral application of SD reduces* Correspondence: yinshijinyf@163.com; huh@anest.wustl.edu
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unless otherwise stated.release of inflammatory cytokines, protects pancreas
function, and markedly improves diabetic symptoms in
a rat model of streptozotocin (STZ)-induced Diabetes
mellitus, a well-recognized autoimmune condition [10,11].
Although these studies have provided convincing evidence
that SD is likely a potent inhibitor of autoimmune disor-
ders, the cellular and molecular mechanisms underlying
the immunomodulatory effect of SD are still poorly
understood.
The pathogenesis of autoimmune diseases involves
activation of effector memory T cells (TEM cells) and/or
class-switched memory B cells, which is evident in a num-
ber of autoimmune diseases including multiple sclerosis
(MS), rheumatoid arthritis, systemic lupus erythematosus,
and type-I diabetes, etc. [12-17]. Activated TEM cells
migrate into tissues, secret inflammatory cytokines,
and contribute to deleterious inflammatory damages
[18]. Memory B cells, especially those belonging to the
class-switched CD27+IgD− subset, are also involved in the
pathogenesis of many autoimmune diseases [19-21].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 SD and LrB inhibit Kv1.3 endogenously expressed by
Jurkat T cells. (A) Representative traces illustrate that SD inhibited
the Kv1.3 current in a Jurkat T cell in a concentration-dependent
manner. (B) Bar chart illustrates that 0.0005% and 0.005% SD significantly
inhibited the Kv1.3 current density (n = 5, *p < 0.05, **p < 0.01). The
inhibitory effect was partially recovered after washout of the drug.
(C) Representative current traces show that LrB inhibited Kv1.3
currents in a Jurkat T cell in a concentration-dependent manner
and the effect was partially reversible. (D) Concentration-response
curve of LrB inhibition of Kv1.3 current in Jurkat T cells. Currents
were normalized to the control and fitted by a Hill equation; EC50
value was 19.9 ± 1.8 μM and Hill slope was 1.1 ± 0.1 (n = 8); the
structure formula of LrB was shown in the inset.
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is an essential signal required for release of inflammatory
cytokines that precedes inflammatory damage in auto-
immune diseases [22]. T cell activation relies on the oper-
ation of voltage-gated and Ca2+-activated K+ channels as
well as calcium release-activated channels (CRAC) channels
which are composed of Orai proteins [23]. Homomeric
voltage-gated Kv1.3 channel is highly expressed in autoreac-
tive TEM cells from MS patients and considered as a critical
therapeutic target for T cell-mediated autoimmune diseases
[24]. Kv1.3 is also found in human B lymphocytes and its
expression is up-regulated in class-switched memory B cells
[25]. Accordingly, extensive efforts have been made to dis-
cover and develop small molecule inhibitors of Kv1.3 as
novel immunosuppressants and immunomodulators [26].
SD possesses great medicinal values because of its rich
flavone components that offer benefits for effective treat-
ment of diseases [6,27,28]. Recent studies have shown
that total flavones, especially its active component LrB,
mediate the effect of SD to regulate functions of several
pain-related ion channels including inhibition of voltage-
gated Na+ currents and TRPV1-mediated cation currents
in primary sensory neurons, which might contribute to
the pain-soothing effect of SD [29-31]. Considering the
fact that SD inhibits the proliferation of activated T-cells
and Kv1.3 plays an essential role in TEM cell activation, we
hypothesize that SD and its active components might
regulate Kv1.3 function. Here we found that SD inhibits
Kv1.3-mediated currents in Jurkat T cells, and further
demonstrated that its essential active component LrB
directly suppresses Kv1.3 by blocking the channel pore,
thereby inhibiting the release of IL-2.
Results
SD and LrB inhibit Kv1.3 in Jurkat T cells
Two major types of K+ channels are expressed by the
human Jurkat T cells: the Kv1.3 (a voltage-dependent K+
channel) [32], and the apamin-sensitive small conductance
Ca2+-dependent K+ channel (SKCa2) which is activated by
a rise in cytosolic Ca2+ [33]. We first examined whether
SD could regulate the activation of endogenous Kv1.3
expressed by human Jurkat T cells which is commonly
used to study T cell signaling [32,34]. To avoid activation
of the SKCa2 channel we used a pipette solution contain-
ing almost zero cytosolic Ca2+. Kv1.3-mediated currents
were elicited by 400 ms depolarizing pulses to +50 mV,
from a holding potential of -60 mV. Bath application of
SD reduced Kv1.3 current by 34.9 ± 12.9% even at a low
concentration of 0.0005% (n = 5). The inhibitory effect of
SD was concentration-dependent (Figure 1B) with the
highest concentration of SD (0.005%) decreasing the Kv1.3
current by 73.6 ± 9.5% (n = 5) (Figure 1A). The suppres-
sive effect of SD was partially reversible after washout
(Figure 1B).LrB is one of the flavonoids in SD and also the most
potent active component of SD that regulates voltage-
gated Na+ channels [31] and TRPV1 [29]. We therefore
tested whether LrB had a similar inhibitory effect as SD
on Kv1.3 in Jurkat T cells. Indeed, LrB alone reduced the
Kv1.3 current in a concentration-dependent manner
with an IC50 of 19.9 ± 1.8 μM (n = 8) (Figure 1D). Like
SD, the suppressive effect of LrB was partly reversible
after washout (Figure 1C). Therefore, it is very likely that
LrB contributes to the inhibitory action of SD on the
Kv1.3.
LrB causes a membrane potential depolarization in
Jurkat T cells
As one of the main resting K+ channels, Kv1.3 is respon-
sible for generating the resting membrane potentials in
the Jurkat T cells [35]. Therefore, suppression of Kv1.3
by LrB should lead to a membrane depolarization of the
Jurkat T cells. To test this hypothesis we measured the
effect of LrB on the membrane potential of Jurkat T cells
by means of current-clamp recording. As expected, 10 μM
LrB depolarized the membrane potential of Jurkat T cells
from −40.9 ± 12.3 mV to −31.7 ± 9.2 mV (n = 10). At
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of Jurkat T cells to −18.6 ± 6.2 mV (n = 10). The effect of
LrB on the membrane potential of Jurkat T cells was par-
tially reversible after washout (Figure 2A and B).
LrB suppresses Ca2+ signaling in Jurkat T cells
As Kv1.3 is involved in generating the resting membrane
potential which drives Ca2+ influx and contributes to
Ca2+ homeostasis in T cells, and a previous study showed
that inhibition of Kv1.3 reduces Ca2+ influx in Jurkat T
cells [35], suggesting that LrB should also reduce Ca2+ in-
flux in Jurkat T cells. To test this hypothesis we performed
live cell Ca2+ imaging using the Ca2+ indicator dye Fura-2
to determine the effect of LrB on changes in [Ca2+]i in the
presence of intracellular Ca2+ store depletion by cyclopia-
zonic acid (CPA), an inhibitor of the sarcoplasmic
reticulum Ca2+-ATPase [36,37].
In the absence of extracellular Ca2+, 10 μM CPA in-
duced a relative small, transient rise of [Ca2+]i in Jurkat
T cells. When 2 mM Ca2+ was added to the Ca2+-free
HBSS, we observed a large Ca2+ influx into the cells
(Figures 3A and D). Pre-treatment of Jurkat T cells with
LrB for 3 min produced a concentration-dependent in-
hibition of the Ca2+ influx (Figure 3B, C, D). At 10 μM,
LrB decreased the change in F340/F380 ratio from
0.24 ± 0.03 to 0.19 ± 0.01 (n = 296) (Figure 3E), and in-
creased the rise time constant from 37.9 ± 11.4 s to 49.
4 ± 2.6 s (n = 296) (Figure 3F). At 30 μM, LrB further
decreased the change in F340/F380 ratio to 0.14 ± 0.03
(Figure 3E), and increased the rise time constant to
74.5 ± 16.9 s (n = 296) (Figure 3F). These results suggest
that LrB is a potent inhibitor of intracellular Ca2+ signal-
ing of T cells through inhibition of Kv1.3.
LrB inhibits IL-2 secretion from activated Jurkat T cells
The cytokine IL-2 is predominantly secreted from acti-
vated T cells and is critical in regulating the balance
between immune tolerance and autoimmunity [38,39].
The secretion of IL-2 is driven by a rise of [Ca2+]i [40].
Since LrB potently suppresses Kv1.3 function andFigure 2 LrB evokes a membrane depolarization in Jurkat T
cells. (A) The representative voltage trace shows that 10 and 30 μM
LrB caused a depolarization of the membrane potential in a Jurkat T
cell in a reversible manner. (B) Statistical data averaged from 10
cells (*P < 0.05).decreases Ca2+ influx in Jurkat T cells we next asked
whether LrB could inhibit IL-2 secretion, which should
result in functional immunosuppression. As a classical
polyclonal stimulator acting through T-cell receptor
complex (TCR)-CD3 complex, PHA has been used to
induce T cell activation and stimulate IL-2 secretion,
which is dependent on an increase of [Ca2+]i [41,42].
We thus used the PHA-stimulated IL-2 secretion in the
growth media as readout. As predicted, IL-2 concentration
measured by ELISA was increased markedly upon stimula-
tion with 10 μg/ml PHA but not vehicle control (Figure 4).
Pre-treatment of the cells with different concentrations of
LrB (10 and 30 μM) for 24 hours significantly reduced
PHA-induced IL-2 secretion in a concentration-dependent
manner. A similar concentration-dependent inhibitory ef-
fect was also observed when the cells were pre-treated with
CP339818, another potent Kv1.3 blocker (Figure 4) [43].
Structural basis of LrB-mediated inhibition of Kv1.3
channel function
We next asked if LrB also inhibits Kv1.3 channels heter-
ologously expressed in HEK293T cells. As expected, LrB
not only reduced the peak amplitude of wild-type
mKv1.3-mediated currents in a concentration-dependent
manner, which recapitulates the phenomenon in the Jur-
kat T cells, but also changed the time course for current
inactivation at high concentrations (Figure 5A). The
steady-state current measured at the end of the depolar-
izing pulse was also markedly decreased by LrB with an
IC50 of 7.2 ± 0.6 μM (n = 8). Interestingly, the inactivation
of mKv1.3 was well fitted to a single exponential function
with a time constant of 113.7 ± 3.8 ms in the absence of
LrB (n = 8) but displayed a double exponential function
with both fast (5.2 ± 0.4 ms) and slow (69.7 ± 5.3 ms, n = 8)
components in the presence of 10 μM LrB (Figure 5A).
The effect of LrB to accelerate the decay time of Kv1.3
channels is reminiscent of the effect of verapamil on
Kv1.3 [44], suggesting that LrB might share the same
binding sites with verapamil in the recombinant Kv1.3
channels. To test this hypothesis, we constructed two
mKv1.3 mutants in which the verapamil binding sites
are disrupted [44]. In one of the mutants we replaced
His404 with a Thr and in the other mKv1.3 mutant
Ala418 was replaced with a Cys.
In HEK293T cells expressing mKv1.3-H404T, LrB
suppressed the steady-state current with an IC50 of
116.5 ± 19.8 μM (n = 8), 16.2 times higher than that of
the wild-type mKv1.3. For mutant Kv1.3-A418C, the
IC50 of LrB inhibition of the steady-state current was
29.1 ± 7.1 μM (n = 8), about 4 times higher than that
for the wild-type mKv1.3 (Figure 5B). Interestingly,
ADWX-1, a potent and selective peptide inhibitor of
Kv1.3 acting through binding to the extracellular pore
turret of the Kv1.3 [45], had a comparable inhibitory
Figure 3 Inhibition of Ca2+ influx by LrB in Jurkat T cells. (A) Representative images were taken in the presence of Ca2+-free extracellular
solution (left) and 6 minutes after 2 mM Ca2+ was added (right) with the intracellular Ca2+ store depleted by 10 μM CPA. (B) and (C) Representative
images illustrate that 10 and 30 μM LrB markedly decreased the intracellular Ca2+ response induced by 2 mM extracellular Ca2+ in CPA-treated Jurkat T
cells. (D) Representative traces show the effect of LrB on store depletion-induced Ca2+ influx. Each trace represents averaged F340/F380 ratio from
about 400 Jurkat T cells. The ratio traces in the presence of 0, 10 and 30 μM LrB are color-coded with black, red and green, respectively. The first [Ca2+]i
peak presents a rapid Ca2+ rise evoked by 10 μM CPA in 0 Ca2+ in extracellular solution, and the second [Ca2+]i peak illustrates the sustained store
depletion-induced Ca2+ influx with an addition of 2 mM Ca2+ in the absence and presence of different concentrations of LrB. The second peak is fitted
with a single exponential function to calculate the rise time constant of store depletion-induced Ca2+ influx. (E) Statistical data summarizes the
net changes in F340/F380 ratios induced by 2 mM extracellular Ca2+, ***P < 0.001. (F) Statistical data illustrates the rise time constant of store
depletion-induced Ca2+ influx in the presence of 0 (Ctl), 10 and 30 μM LrB, *P < 0.05, **P < 0.01.
Figure 4 LrB inhibits IL-2 secretion from activated Jurkat T cells.
The concentrations of IL-2 in cell growth media were measured by
ELISA. Jurkat T cells were activated by PHA (10 μg/ml) for 24 hours.
LrB (30 and 100 μM), CP-339818 (CP, 3 and 10 μM) were added
simultaneously with PHA. **P < 0.01, ***P < 0.0001, n = 6.
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A418C mutants (Figure 5C and D). These data suggest
that LrB, like verapamil, is a deep pore blocker of the
mKv1.3, presumably interacting directly through His404
and A418 residues.
Discussion
SD is one of the rare traditional herb remedies that have
been widely used in clinical practice because of its effect-
iveness in treating a variety of diseases [6]. SD possesses
complex components and displays a variety of pharmaco-
logical activities. Recent exciting studies have significantly
advanced our knowledge about the pharmacological activ-
ities of SD [46,47]. Further studies using electrophysio-
logical recordings have revealed that LrB, cochinchinenin
A and cochinchinenin B are the three main active ingredi-
ents of SD and potentially mediate SD’s analgesic effect
by inhibiting voltage-gated Na+ channels and the pain-
initiating TRPV1 channels in the primary sensory neurons
[47-50]. In addition to its analgesic effect, SD’s immuno-
modulatory activity has also gained widespread attention
in recent years [51,52] and is considered as the main rea-
son for its effectiveness in the treatment of diabetes [11].
However, unlike its analgesic effect, the molecular targets
of SD’s immunomodulatory effect have not been identified
and the active ingredients mediating the immunomodula-
tory effects have not been determined. Here we show that
both SD and its active component LrB have an inhibitory
Figure 5 Point mutations in the selective filter region reduced the inhibitory effect of LrB on mKv1.3. (A) Representative mKv1.3 current
traces at +50 mV in the absence (Ctl) or presence of 3 or 10 μM LrB. (B) Concentration-response curves of LrB inhibition on currents mediated by
the wild-type or mKv1.3 mutants taken at +50 mV. Each data point represents mean ± SE of at least five experiments. (C) Representative mKv1.3
current traces at +50 mV in the absence (Ctl) or presence of 10 or 100 pM ADWX-1. (D) Concentration-response curves of ADWX-1 inhibition on
currents mediated by the wild-type or mKv1.3 mutants taken at + 50 mV. Each data point represents mean ± SE of at least five experiments.
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cytes. LrB also inhibits the release of inflammatory cytock-
ine, IL-2, from the activated Kv1.3-expressing Jurkat T
cells. Furthermore, we show that two amino acid residues
in the inner pore region are required for the inhibitory
action of LrB on Kv1.3. Our results suggest that LrB and
its analogs might exert their immunomodulatory effects
by directly blocking the Kv1.3 channels expressed by both
T and B lymphocytes.
Autoimmune diseases occur when the Kv1.3 expres-
sion level increases sharply in the proliferating TEM cell
membrane [53]. Indeed, Kv1.3 blockers can inhibit the
activation and proliferation of the TEM cells [54]. There
is also a growing body of evidence suggesting that Kv1.3
channel blockers have beneficial therapeutic effect on
rheumatoid arthritis [55], autoimmune encephalitis [54]
and other autoimmune diseases. Consistent with being a
Kv1.3 inhibitor, SD effectively reduces islet β cell damage
in a rodent model of STZ-induced type I diabetes and
increases levels of plasma insulin, thereby lowering
blood glucose [10], suggesting that SD has a therapeutic
effect on autoimmune diseases. In vitro studies show that
SD also inhibits the activation and proliferation of T lym-
phocytes [51], excessive activation of which is associatedwith autoimmune diseases. Since TEM cell proliferation is
directly associated with the pathogenesis of autoimmune
diseases, these findings strongly suggest that therapeutic
benefit of SD on autoimmune diseases likely results from
inhibition of the activation and proliferation of T lympho-
cytes [53]. In this study, we demonstrate that SD has a
blocking effect on Kv1.3 channels endogenously expressed
by the human Jurkat T lymphocytes. LrB, the main active
ingredient of SD, can also block the Kv1.3 channel, which
is reminiscent of its inhibitory action on the voltage-gated
Na+ channels expressed by the primary sensory neurons
[31]. These findings not only help to explain the immuno-
modulatory activity of SD, but might also provide a mo-
lecular basis for its contribution to increased insulin
sensitivity and improvement of type I diabetes [56].
Similar to other Kv1.3 blockers, application of LrB
acutely depolarizes the cell membrane potential of Jurkat
T cells (Figure 2) [35], which will weaken driving force
for the extracellular Ca2+ influx and reduce the [Ca2+]i
in Jurkat T cells (Figure 5) [57]. It is well-known that an
increase of [Ca2+]i level is directly associated with up-
regulated transcription and release of inflammatory
mediators including IL-2, TNFα, etc. [58]. Therefore,
Kv1.3 channel blockers can inhibit the release of
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increase in Jurkat T cells [57,59]. Our studies found that
LrB exerts many similar effects as other Kv1.3 channel
blockers [35,57], for instance, inhibition of PHA-induced
IL-2 release from the Jurkat T cells. These findings further
support that LrB might be an active immunoregulatory in-
gredient of SD.
With the establishment of Kv1.3 channel as an excel-
lent drug target for autoimmune diseases [53], extensive
efforts have been made to develop selective and efficient
Kv1.3 channel blockers and provide lead drugs for the
treatment of autoimmune diseases [26,60,61]. Currently,
Kv1.3 channel blockers have two main sources: 1) poly-
peptide toxins (20–50 amino acid residues) mainly from
animal poisonous glands such as in scorpions [60], anem-
ones [62]. Most of these peptide toxins block the channel
mouth (outer vestibular) to inhibit Kv1.3 [45]; 2) small
organic molecules mainly from medicinal plants. They
usually bind to the inner pore region of Kv1.3 and
serve as open channel blockers to accelerate the current
decay [44]. Our studies show that LrB produces a
concentration-dependent inhibition of mKv1.3 heterolo-
gously expressed by HEK293T cells and displays charac-
teristics of small molecule blockers by accelerating the
current decay of mKv1.3 channels. The blocking effect of
LrB shares certain similarities as that of another Kv1.3
blocker verapamil and might share some common verap-
amil recognition sites located in the selectivity filter region
of Kv1.3 since mutants carrying mutations disrupting key
verapamil interaction site also significantly attenuate LrB
inhibition of Kv1.3 [63].
In summary, the current study demonstrates that the
traditional herb medicine SD and its main active ingredi-
ent LrB are blockers of Kv1.3 channels. We also show
that LrB causes a membrane depolarization and inhibits
IL-2 release from the Jurkat T cells. Furthermore, we
have identified two amino acid residues on the inner
pore of mKv1.3 that are critical to LrB inhibition. These
findings provide molecular and cellular basis of the im-
munomodulatory activities mediated by SD and its active
component LrB.
Materials and methods
Cell culture, vector constructs, and transfection
Jurkat E6-1 T cells (ATCC TIB152) and HEK293T cells
(ATCC ACS4500) were maintained in RPMI medium
1640 (Invitrogen, Carlsbad, CA, USA) and Dulbecco's
modified Eagle's medium (DMEM) (Life Technologies,
GrandIsland, NY, USA), supplemented with 10% fetal
bovine serum (Life Technologies), 100 units/ml peni-
cillin, 100 μg/ml streptomycin, respectively. Cells were
cultured in a humidified incubator at 37°C with 5%
CO2. cDNAs encoding mKv1.3 in pSP64 (a generous
gift from Prof. Stephan Grissmer, University of Ulm,Ulm, Germany) were subcloned into the XhoI/BamH I
sites of pIRES2-EGFP (Clontech, Inc., Mountain View, CA,
USA). All mKv1.3 mutants were made using QuikChange
II XL mutagenesis kit (Agilent Technologies, Inc., Santa
Clara,CA, USA) according to manufacturer's directions and
confirmed by DNA sequencing. HEK293T cells were
transiently transfected with wild-type and individual
mKv1.3 mutants using Lipofectamine 2000 (Invitrogen)
and maintained in DMEM at 37°C for 24 hrs before
experiments.
Solutions and chemicals
The External solution used to record Kv1.3 currents
contained (in mM): 5 KCl, 140 NaCl, 10 Hepes, 2 CaCl2,
1 MgCl2, and 10 D-glucose (pH 7.4 with NaOH). The
internal solution contained (in mM): 140 KCl, 1 MgCl2,
1 EGTA, 3 Na2ATP, and 10 Hepes (pH 7.2 with KOH).
ADWX-1 was from Wuhan More Biotechnology Co, Ltd
(Wuhan, China) and SD and LrB were from Shanghai
Pure One Biotechnology (Shanghai, China). All other
chemicals were from Sigma (St. Louis, MO, USA).
Electrophysiology
Whole-cell patch-clamp recordings were performed using
an EPC 10 amplifier (HEKA Elektronik, Lambrecht/Pfalz,
Germany) at room temperature (22-24°C). Pipettes pulled
from borosilicate glass (BF 150-86-10; Sutter Instrument
Company, Novato, CA, USA) had resistances of 2–4 MΩ
when filled with the internal solution. Kv1.3 currents were
elicited by a +50 mV, 400 ms depolarizing pulse from a
holding potential of −60 mV every 30 s. The membrane
potential was measured in zero current (I = 0) model using
whole-cell current-clamp technique.
Live cell Ca2+ imaging
Jurkat T cells were loaded with 4 μM Fura-2 AM (Life
Technologies) for 60 min at 37°C. Cells were then
washed 3 times and incubated in Hank's Balanced Salt
Solution (HBSS) for 30 min at room temperature before
use. Fluorescence at 340 nm and 380 nm excitation
wavelengths was recorded on an inverted Nikon Ti-E
microscope equipped with 340, 360 and 380 nm excita-
tion filter wheels using NIS-Elements imaging software
(Nikon Instruments Inc., Melville, NY, USA). Fura-2 ratios
(F340/F380) reflect changes in [Ca2+]i upon stimulation.
Data were obtained from 100–250 cells in time-lapse im-
ages from each coverslip.
IL-2 secretion measurements
IL-2 secretion from Jurkat T cells was measured using
an ELISA kit (eBioscience, San Diego, CA, USA) follow-
ing manufacturer's instructions. Cells were centrifuged
at 1500 rpm for 10 min, and the supernatants were col-
lected to measure IL-2 concentrations. Reactions were
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body and stopped with phosphoric acid (1 M). Absorbance
was measured at 450 nm. Each experiment was repeated at
least three times in duplicate.
Statistical analysis
All data are presented as mean ± SEM for n independent
observations. Statistical analysis of differences between
groups was carried out using paired t-test or ANOVA.
P < 0.05 was considered significantly different.
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